Press Room

Rui Loureiro speaker at The Scale Up of Chemical Processes Conference

Start
Wednesday, June 21, 2017 - 00:00
End
Wednesday, June 21, 2017 - 00:00
Location: New York, United States

Rui Loureiro is guest speaker at The Scale-Up of Chemical Processes
Date: 22 June
Time: 9:15 AM

The Scale-Up of Chemical Processes is one of the major international forums for the discussion of interesting aspects of scale-up in the pharmaceutical, fine chemical and allied fields. This broad-based conference is the best place to discuss the latest ideas and techniques with the key people in the industry presenting case studies and examples of some of the pitfalls and problems they encountered and how they overcame them.

Topics

  • Achieving greater process efficiency, yield and throughput
  • Eliminating unsafe and non-green processes and materials
  • Decreasing the costs and number of steps involved

Also in the Press Room

See All

Integrated approach simplifies development, reduces risk, and supports scalable manufacturing. Hovione and Industrial Design Consultancy Ltd.’s (IDC) lead single-use nasal dry powder device is now available for commercial partnerships. Hovione and IDC have completed the device design and established initial device manufacturing and supply capability, enabling pharmaceutical partners to leverage existing capsule filling infrastructure. This approach simplifies development, reduces cost and risk, and helps shorten timelines to the clinic and commercialization. “This milestone marks an important step in the evolution of our collaboration with IDC — from device innovation to a fully integrated intranasal drug delivery platform,” said Márcio Temtem, Ph.D., Vice President, Strategic Business Management, Hovione. “As the industry looks for faster, more reliable ways to bring complex therapies to patients, integration becomes critical. By bringing together nasal particle engineering science, formulation manufacturing and filling, and device technologies into a single offering, we enable a more seamless and predictable development journey, accelerating the path to market for intranasal therapies.” The nasal delivery device enables broad and targeted nasal deposition flexibility while delivering maximum usability and reliability. With a patented design and manufacturing process established, the platform is available for partnering with pharmaceutical companies on an exclusive basis as part of Hovione’s integrated offering for inhalation and nasal drug development and manufacturing. Additionally, IDC’s Managing Director, Stephen Knowles Ph.D., said the companies are now “well-advanced” with the development of a multi-use device to support an even wider range of therapies and patient needs. Read the full article at ContractPharma.com    

Press Clipping

Hovione, IDC Launch Intranasal Drug Delivery Platform

May 07, 2026